

Eloisa Jantus-Lewintre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1146769/publications.pdf>

Version: 2024-02-01

119
papers

2,462
citations

201385

27
h-index

223531

46
g-index

125
all docs

125
docs citations

125
times ranked

4573
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3216.	1.7	4
2	dPCR application in liquid biopsies: divide and conquer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 3-15.	1.5	15
3	Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. <i>Molecular Oncology</i> , 2021, 15, 43-56.	2.1	18
4	3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. <i>Materials Science and Engineering C</i> , 2021, 122, 111914.	3.8	32
5	Potential Non-Invasive Biomarkers for Early Diagnosis of Oral Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 1658.	1.0	23
6	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. <i>European Journal of Cancer</i> , 2021, 149, 61-72.	1.3	21
7	Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2514.	1.7	19
8	Differentially methylated genes in proliferative verrucous leukoplakia reveal potential malignant biomarkers for oral squamous cell carcinoma. <i>Oral Oncology</i> , 2021, 116, 105191.	0.8	11
9	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	0.5	37
10	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. <i>Molecular Oncology</i> , 2021, 15, 2363-2376.	2.1	16
11	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2950.	1.7	12
12	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. <i>Cancers</i> , 2021, 13, 3016.	1.7	38
13	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	1.3	3
14	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	1.5	20
15	Oral microbiome in Proliferative Verrucous Leukoplakia exhibits loss of diversity and enrichment of pathogens. <i>Oral Oncology</i> , 2021, 120, 105404.	0.8	7
16	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1074-1083.	1.3	14
17	A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 575-582.	1.5	21
18	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102978.	2.0	79

#	ARTICLE	IF	CITATIONS
19	Comprehensive cross-platform comparison of methodologies for noninvasive EGFR mutation testing: Results of the RING observational trial.. Journal of Clinical Oncology, 2020, 38, e21518-e21518.	0.8	1
20	Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy. Annals of Oncology, 2019, 30, v776-v777.	0.6	0
21	Characterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer. Annals of Oncology, 2019, 30, v587.	0.6	0
22	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports, 2019, 9, 15400.	1.6	13
23	Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. Cell Death and Disease, 2019, 10, 660.	2.7	68
24	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Lung Cancer, 2019, 134, 72-78.	0.9	24
25	Lung tumorspheres as a drug screening platform against cancer stem cells. Annals of Oncology, 2019, 30, ii8.	0.6	0
26	Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers. Annals of Oncology, 2019, 30, ii10-ii11.	0.6	0
27	P2.03-08 Analysis of Immunosuppressive Factors Produced by CSCs Revealed Galectin-3 as Immune Modulator with Prognostic Value in NSCLC Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S685.	0.5	0
28	MA04.09 Study of Exosomes in NSCLC for Biomarkers Searching. Journal of Thoracic Oncology, 2019, 14, S263.	0.5	0
29	ES25.01 Liquid Biopsy: State of the Science. Journal of Thoracic Oncology, 2019, 14, S72.	0.5	0
30	MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S261.	0.5	0
31	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	1.0	17
32	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Annals of Oncology, 2019, 30, 290-296.	0.6	55
33	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, 651-651.	0.7	18
34	Passenger mutations in cancer evolution. Cancer Reports and Reviews, 2019, 3, .	0.6	0
35	Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.. Journal of Clinical Oncology, 2019, 37, e20685-e20685.	0.8	0
36	Osimertinib and dihydroartemisinin: A novel drug combination targeting head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, e17526-e17526.	0.8	0

#	ARTICLE	IF	CITATIONS
37	EP912â€¦Characterization of the tumour microenvironment in high-grade serous ovarian cancer (HGSOC): prognostic value of the lymphocytic infiltration patterns and immune-related genes. , 2019, , .		0
38	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. Cancer Treatment and Research Communications, 2018, 15, 21-31.	0.7	9
39	Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression. Targeted Oncology, 2018, 13, 175-187.	1.7	31
40	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
41	Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1164-1176.	2.5	77
42	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Annals of Oncology, 2018, 29, 200-208.	0.6	25
43	EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. Critical Reviews in Oncology/Hematology, 2018, 126, 52-63.	2.0	26
44	High-throughput screening of new drugs targeting lung CSCs. Annals of Oncology, 2018, 29, viii668.	0.6	0
45	CD5 and CD6: Evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer. Annals of Oncology, 2018, 29, viii657.	0.6	0
46	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1464-1470.	2.9	62
47	An expression signature characterizes cancer stem cells from lung adenocarcinoma patients. Annals of Oncology, 2018, 29, viii666.	0.6	0
48	Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clinical and Translational Oncology, 2018, 20, 1422-1429.	1.2	6
49	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget, 2018, 9, 4395-4410.	0.8	37
50	New generation of cancer stem cells inhibitors in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e20545-e20545.	0.8	0
51	A gene expression signature to characterize human lung adenocarcinoma cancer stem cells.. Journal of Clinical Oncology, 2018, 36, e20547-e20547.	0.8	0
52	Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.. Journal of Clinical Oncology, 2018, 36, 9101-9101.	0.8	0
53	Abstract 3056: Lung tumor spheres as in vitro platform for testing new therapeutic strategies against cancer stem cells. , 2018, , .		0
54	Profile of the Roche cobasÂ® EGFR mutation test v2 for non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2017, 17, 209-215.	1.5	135

#	ARTICLE	IF	CITATIONS
55	Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevacizumab: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 403-408.	0.4	8
56	P1.05-013 Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S621.	0.5	0
57	P1.05-014 Stemness Gene Expression Profile of Tumorspheres from Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S621-S622.	0.5	0
58	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1260214.	2.1	11
59	Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. <i>Annals of Oncology</i> , 2017, 28, 2248-2255.	0.6	95
60	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	0.7	0
61	MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. <i>Oncotarget</i> , 2017, 8, 56143-56157.	0.8	28
62	Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways. <i>Annals of Oncology</i> , 2017, 28, v453.	0.6	1
63	New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. <i>Journal of Thoracic Disease</i> , 2017, 9, S1332-S1345.	0.6	13
64	Exosomes in semen: opportunities as a new tool in prostate cancer diagnosis. <i>Translational Cancer Research</i> , 2017, 6, S1331-S1338.	0.4	11
65	Abstract 1918: Gene characterization of lung-tumorspheres for their usage as an in vitro screening platform for testing new therapeutic strategies. , 2017, , .		0
66	Abstract 4424: Cancer stem cells-related microRNAs have prognostic implications in non-small cell lung cancer. , 2017, , .		0
67	Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 12904-12916.	0.8	73
68	Circulating tumor cells versus circulating tumor DNA in lung cancerâ€”which one will win?. <i>Translational Lung Cancer Research</i> , 2016, 5, 466-482.	1.3	72
69	Molecular subtyping of colon cancer (CC) based on mutational status of RAS, BRAF, and DNA mismatch repair (MMR) proteins. Prognostic value.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15094-e15094.	0.8	2
70	Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. <i>Oncotarget</i> , 2016, 7, 52849-52861.	0.8	33
71	Differential expression of tumorspheres in CSC-markers and signaling pathways from non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23276-e23276.	0.8	0
72	Lung tumorspheres as a platform for testing new therapeutic strategies in lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23177-e23177.	0.8	0

#	ARTICLE	IF	CITATIONS
73	EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e23039-e23039.	0.8	0
74	Abstract 3354: Characterization of lung tumorspheres by gene expression and flow cytometry: differential expression in CSC-related markers and signaling pathways. , 2016, , .		0
75	Facilitated Anion Transport Induces Hyperpolarization of the Cell Membrane That Triggers Differentiation and Cell Death in Cancer Stem Cells. Journal of the American Chemical Society, 2015, 137, 15892-15898.	6.6	109
76	Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Diseases, 2015, 21, 899-904.	1.5	27
77	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage III Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1067-1075.	0.5	15
78	Prognostic value of miRNAs in resected lung adenocarcinomas.. Journal of Clinical Oncology, 2015, 33, 7532-7532.	0.8	0
79	Analysis of the prognostic value of the tumor immunologic profile in resectable NSCLC.. Journal of Clinical Oncology, 2015, 33, 11052-11052.	0.8	0
80	Isolation and characterization of lung cancer sphere-forming cells as platforms for the development of new therapeutic strategies.. Journal of Clinical Oncology, 2015, 33, e22190-e22190.	0.8	0
81	Abstract 4010: Prognostic role of miRNAs in resectable non-small cell lung cancer. , 2015, , .		0
82	Abstract 4330: Immune checkpoint expression score is an independent prognostic biomarker in resectable non-small cell lung cancer. , 2015, , .		0
83	miRNA detection methods and clinical implications in lung cancer. Future Oncology, 2014, 10, 2279-2292.	1.1	29
84	MicroRNAs: Promising New Antiangiogenic Targets in Cancer. BioMed Research International, 2014, 2014, 1-14.	0.9	48
85	A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer. Annals of Surgical Oncology, 2014, 21, 612-620.	0.7	24
86	Oncological translational research in the Spanish national health system: the INTRO study. Clinical and Translational Oncology, 2014, 16, 686-695.	1.2	0
87	Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers.. Journal of Clinical Oncology, 2014, 32, 8083-8083.	0.8	0
88	Prognostic role of immune checkpoint-related genes in resectable lung adenocarcinomas.. Journal of Clinical Oncology, 2014, 32, 11085-11085.	0.8	0
89	Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22.2 for migratory capacity in head and neck squamous cell carcinomas. BMC Cancer, 2013, 13, 116.	1.1	19
90	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	3.0	127

#	ARTICLE	IF	CITATIONS
91	Analysis of the prognostic impact of Treg-related genes in tumor and stroma in resectable NSCLC.. Journal of Clinical Oncology, 2013, 31, 11073-11073.	0.8	1
92	The European Thoracic Oncology Platform Lungscope project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 7514-7514.	0.8	2
93	Ratios between VEGF ligands and receptors in tumor and stroma have impact on the outcome in resectable NSCLC.. Journal of Clinical Oncology, 2013, 31, e22147-e22147.	0.8	2
94	Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.. Journal of Clinical Oncology, 2013, 31, 11010-11010.	0.8	1
95	Update on biomarkers for the detection of lung cancer. Lung Cancer: Targets and Therapy, 2012, 3, 21.	1.3	22
96	Prognostic role of FOXP3/CD4 ratio in resectable NSCLC.. Journal of Clinical Oncology, 2012, 30, 7058-7058.	0.8	0
97	miRNA profiling in resectable NSCLC by multiplex next-generation sequencing.. Journal of Clinical Oncology, 2012, 30, 7060-7060.	0.8	1
98	Prognostic value of "angiogenic" risk score in early-stage NSCLC.. Journal of Clinical Oncology, 2012, 30, 10594-10594.	0.8	0
99	The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer, 2011, 72, 365-369.	0.9	43
100	Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer, 2011, 74, 326-331.	0.9	48
101	Chemotherapy-Induced Neutropenia Does Not Correlate With DNA Repair Gene Polymorphisms and Treatment Efficacy in Advanced Non-Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2011, 12, 224-230.	1.1	17
102	Analysis of the Prognostic Value of Soluble Epidermal Growth Factor Receptor Plasma Concentration in Advanced Non-Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2011, 12, 320-327.	1.1	15
103	The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. Clinical and Translational Oncology, 2011, 13, 396-400.	1.2	10
104	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical and Translational Oncology, 2011, 13, 411-418.	1.2	0
105	Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 286-290.	0.5	75
106	Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia, 2010, 24, 788-797.	3.3	132
107	Analysis of chronic lymphocytic leukemia transcriptomic profile: differences between molecular subgroups. Leukemia and Lymphoma, 2009, 50, 68-79.	0.6	21
108	BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 773-780.	0.6	16

#	ARTICLE	IF	CITATIONS
109	Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 280-284.	1.7	17
110	ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1422-1424.	1.7	5
111	Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. <i>Clinical and Translational Oncology</i> , 2006, 8, 805-811.	1.2	4
112	Analysis of B-CLL Transcriptomic and Proteomic Profiles: Differences between Molecular Subgroups.. <i>Blood</i> , 2006, 108, 2088-2088.	0.6	0
113	Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2005, 99, 253-261.	0.8	78
114	Characterization of the Proteomic and Genomic Profiles of Chronic Lymphocytic Leukemia Patients with Distinct Clinical Prognosis According to the Mutational Status of the IgVH and BCL6 and Expression Level of CD38 and ZAP70.. <i>Blood</i> , 2005, 106, 3272-3272.	0.6	0
115	Treatment of B-CLL Cells with Bortezomib and Rituximab Reduces Cell Viability In Vitro... <i>Blood</i> , 2004, 104, 2798-2798.	0.6	1
116	Influence of Different Complement Sources in Apoptosis of B-CLL Cells with Rituximab.. <i>Blood</i> , 2004, 104, 4782-4782.	0.6	0
117	P511 Inflammatory response in acute myocardial infarction patients: a long-term follow-up. <i>European Heart Journal</i> , 2003, 24, 80.	1.0	0
118	Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. <i>American Heart Journal</i> , 2002, 143, 814-820.	1.2	80
119	Characterization of 17 β -hydroxysteroid dehydrogenase type 1 in choriocarcinoma cells: regulation by basic fibroblast growth factor. <i>Molecular and Cellular Endocrinology</i> , 1994, 104, 1-9.	1.6	48